STAT

How well can you predict the outcome of clinical trials? Not as well as you may think

Researchers might not be as great at determining the likelihood of a clinical trial’s success as they think they are.

If researchers were better at forecasting the results of clinical trials — and, say, could avoid having to run trials that will inevitably fail — more resources could be devoted to trials that might succeed.

But, it turns out, researchers might not be great at determining the likelihood of a trial’s success.

In unpublished research, McGill bioethicist Jonathan Kimmelman and colleagues asked cancer experts to forecast the probability of more than a dozen clinical trials hitting their primary endpoint. They found that the predictions overall were not very accurate, and, if anything, were too pessimistic.

Kimmelman presented his research last week at Harvard Medical School and spoke to STAT afterward about the importance of forecasting in clinical trials.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About MDMA For PTSD, A CRISPR Treatment For Blindness, And More
An FDA advisory panel will deliberate on June 4 whether to recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.

Related Books & Audiobooks